Archie Tse

4.4k citations

59 papers · 3.3k indexed · 1 hit paper · h-index 23

Oncology top 1%
Molecular Biology top 5%
Pulmonary and Respiratory Medicine top 2%
Cell Biology top 5%
Surgery top 10%

Co-authors: Gary K. Schwartz Richard D. Carvajal David P. Kelsen Manish A. Shah Nancy E. Kemeny Jinru Shia David S. Klimstra Leonard B. Saltz
Topics: Cancer therapeutics and mechanisms (13 papers)Cancer-related Molecular Pathways (13 papers)Cancer Immunotherapy and Biomarkers (11 papers)
Cited by: Oncology Pulmonary and Respiratory Medicine Hepatology
Journals: Journal of Biological Chemistry Journal of Clinical Oncology Blood
Partner nations: United States United Kingdom China

In The Last Decade

Archie Tse

57 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry

2005 848 citations Jinru Shia, Nancy E. Kemeny et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Archie Tse

Since Specialization

Citations

This map shows the geographic impact of Archie Tse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Archie Tse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Archie Tse more than expected).

Fields of papers citing papers by Archie Tse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Archie Tse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Archie Tse. The network helps show where Archie Tse may publish in the future.

Co-authorship network of co-authors of Archie Tse

This figure shows the co-authorship network connecting the top 25 collaborators of Archie Tse. A scholar is included among the top collaborators of Archie Tse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Archie Tse. Archie Tse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	LBA48 BURAN: A phase III study of buparlisib (BUP) plus paclitaxel (PAC) in patients with PD-1(PD-L1)-pretreated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) 2025 ·Annals of Oncology ·Denis Soulières,Yi‐Chun Liu,Kedar Kirtane,Stefan Kasper‐Virchow,Tomasz Rutkowski,Federico de la Rosa,(unknown),Francis P. Worden,(unknown),Anil K. Giri,Amaury Daste,Erika Hitre,Akihito Tsuji,(unknown),Ye Guo,(unknown),(unknown),(unknown),Archie Tse,Lisa Licitra	0
2	Dual CTLA‐4 and PD‐1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first‐in‐human, dose‐escalation, and dose‐expansion study 2024 ·Cancer ·(unknown),Dusan Kotasek,Morteza Aghmesheh,Thomas Yau,Rasha Cosman,Amy Prawira,(unknown),Stephen L. Chan,Andrew Mant,Richard Eek,Robert Zielinski,(unknown),(unknown),(unknown),Fei Li,(unknown),Archie Tse	1
3	Tumor growth inhibition‐overall survival modeling in non‐small cell lung cancer: A case study from GEMSTONE‐302 2023 ·CPT Pharmacometrics & Systems Pharmacology ·Yucheng Sheng,Shu‐Wen Teng,Jingru Wang,Hao Wang,Archie Tse	9
4	Clinical pharmacokinetics and pharmacodynamics of ivosidenib in Chinese patients with relapsed or refractory IDH1-mutated acute myeloid leukemia 2023 ·European Journal of Clinical Pharmacology ·(unknown),(unknown),Siyuan Wang,Archie Tse,Yucheng Sheng	1
5	A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer 2023 ·British Journal of Cancer ·Daphne Day,John Park,Jermaine Coward,Ben Markman,Charlotte Lemech,James Kuo,Amy Prawira,Michael P. Brown,(unknown),Dusan Kotasek,Robert Matthew Strother,Rasha Cosman,(unknown),(unknown),(unknown),(unknown),Rachel Wu,(unknown),Archie Tse	4
6	138P Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors 2021 ·Annals of Oncology ·(unknown),Thomas Yau,Rasha Cosman,(unknown),Miranda A. Moore,Stephen L. Chan,Andrew Mant,Richard Eek,(unknown),(unknown),H. Wang,(unknown),Archie Tse	2
7	987P A phase Ib study of the PD-1 antagonist CS1003 plus lenvatinib (LEN) in Chinese patients (pts) with the first-line (1L) unresectable hepatocellular carcinoma (uHCC) 2020 ·Annals of Oncology ·Lin Shen,(unknown),Ye Guo,W. Li,(unknown),Zhigang Ma,(unknown),Na Wang,Jingxian Ni,Qi Qi,Yan Ma,Zike Qin,Archie Tse	9
8	Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition 2018 ·Cancer Research ·Jo Ishizawa,Kenji Nakamaru,Takahiko Seki,(unknown),Kensuke Kojima,Dhruv Chachad,Ran Zhao,Lauren Heese,Wencai Ma,Man Chun John,Courtney D. DiNardo,Sherry Pierce,Keyur P. Patel,Archie Tse,R. Eric Davis,Arvind Rao,Michael Andreeff	44
9	Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas 2018 ·Annals of Oncology ·Kevin J. Harrington,Joshua Brody,(unknown),James Strauss,Sašo Čemerski,(unknown),Archie Tse,Anuradha Khilnani,Aurélien Marabelle,Talia Golan	201
10	A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development 2017 ·Contemporary Clinical Trials ·Cong Chen,Keaven M. Anderson,Devan V. Mehrotra,Eric H. Rubin,Archie Tse	41
11	Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase 2010 ·Cell Cycle ·Samuel McNeely,Chiara Conti,Tahir Sheikh,(unknown),Sonya Zabludoff,Yves Pommier,Gary K. Schwartz,Archie Tse	68
12	Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival 2009 ·Annals of Oncology ·William R. Jarnagin,Lawrence H. Schwartz,David H. Gültekin,Mithat Gönen,Dana Haviland,Jinru Shia,(unknown),Yuman Fong,Ronald P. DeMatteo,Archie Tse,Leslie H. Blumgart,Nancy E. Kemeny	138
13	A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies 2009 ·Cancer Chemotherapy and Pharmacology ·Archie Tse,Nian Wu,Dina Patel,Dana Haviland,Nancy E. Kemeny	10
14	A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors 2008 ·Clinical Cancer Research ·Archie Tse,David S. Klimstra,Mithat Gönen,(unknown),Tahir Sheikh,Rachel Sikorski,Richard D. Carvajal,(unknown),(unknown),Eileen M. O’Reilly,Ki Wook Chung,Robert G. Maki,Robert A. Lefkowitz,Karen T. Brown,Katia Manova‐Todorova,Nian Wu,Merrill J. Egorin,David P. Kelsen,Gary K. Schwartz	49
15	AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies 2008 ·Molecular Cancer Therapeutics ·Sonya Zabludoff,Chun Deng,Michael Grondine,(unknown),Susan Ashwell,Benjamin Caleb,Stephen Green,(unknown),Candice L. Horn,James W. Janetka,Dongfang Liu,Elizabeth Mouchet,Shannon Ready,(unknown),Christophe Quéva,Gary K. Schwartz,Karen J. Taylor,Archie Tse,Graeme E. Walker,(unknown)	333
16	CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons In vitro and In vivo 2007 ·Clinical Cancer Research ·Archie Tse,Katherine G. Rendahl,Tahir Sheikh,(unknown),(unknown),Millicent Embry,Sylvia Ma,Edward J. Moler,(unknown),Daniel E. Lopes de Menezes,Barbara Hibner,Thomas G. Gesner,Gary K. Schwartz	117
17	A phase I clinical and pharmacokinetic study of escalating doses of fixed rate and escalating infusion duration of gemcitabine given via an intrahepatic pump for patients with hepatic metastases 2006 ·Journal of Clinical Oncology ·Archie Tse,Greer A. Raggio,M. Morse,Nancy E. Kemeny	1
18	Potentiation of Cytotoxicity of Topoisomerase I Poison by Concurrent and Sequential Treatment with the Checkpoint Inhibitor UCN-01 Involves Disparate Mechanisms Resulting in Either p53-Independent Clonogenic Suppression or p53-Dependent Mitotic Catastrophe 2004 ·Cancer Research ·Archie Tse,Gary K. Schwartz	76
19	Mutations in the Reduced Folate Carrier Gene Which Confer Dominant Resistance to 5,10-Dideazatetrahydrofolate 1998 ·Journal of Biological Chemistry ·Archie Tse,Kevin E. Brigle,Shirley M. Taylor,Richard G. Moran	52
20	Cellular Folates Prevent Polyglutamation of 5,10-Dideazatetrahydrofolate 1998 ·Journal of Biological Chemistry ·Archie Tse,Richard G. Moran	29

About Archie Tse

Archie Tse is a scholar working on Oncology, Hepatology and Cancer Research, having authored 59 papers that have together received 3.3k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (13 papers), Cancer-related Molecular Pathways (13 papers) and Cancer Immunotherapy and Biomarkers (11 papers). The work is most often cited by research in Oncology (2.0k citations), Pulmonary and Respiratory Medicine (947 citations) and Hepatology (210 citations). Archie Tse has collaborated with scholars based in United States, United Kingdom and China. Frequent co-authors include Gary K. Schwartz, Richard D. Carvajal, David P. Kelsen, Manish A. Shah, Nancy E. Kemeny, Jinru Shia, David S. Klimstra, Leonard B. Saltz, Deborah Schrag and Audrey Hamilton. Their work appears in journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact